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ER

:   estrogen receptor

FOXO1

:   forkhead box protein O1

MCAD

:   medium‐chain acyl CoA dehydrogenase

PGC‐1β

:   peroxisome proliferator‐activated receptor‐gamma coactivator‐1β

Tg

:   transgenic

FOXO1 (Gene symbol; *Foxo1*) is a forkhead‐type transcription factor, whose expression is markedly upregulated in skeletal muscles during atrophy, that is, under conditions such as starvation, unloading (plaster cast), and denervation \[[1](#feb412898-bib-0001){ref-type="ref"}, [2](#feb412898-bib-0002){ref-type="ref"}\]. Transgenic (Tg) overexpression of FOXO1 in skeletal muscles causes muscle atrophy \[[3](#feb412898-bib-0003){ref-type="ref"}\], with increased expression of atrophy‐related genes, including cathepsin L (*Ctsl*) and lysosomal proteinase \[[3](#feb412898-bib-0003){ref-type="ref"}, [4](#feb412898-bib-0004){ref-type="ref"}\]. In the skeletal muscles of FOXO1‐knockout (FOXO1‐KO) mice, the increase in cathepsin L gene expression caused by fasting was attenuated \[[4](#feb412898-bib-0004){ref-type="ref"}, [5](#feb412898-bib-0005){ref-type="ref"}\]. FOXO1 activation mostly increases the expression of its target genes \[[6](#feb412898-bib-0006){ref-type="ref"}, [7](#feb412898-bib-0007){ref-type="ref"}\]; however, the expression of some genes such as IGFBP5 (*Igfbp5*) and musclin (or osteocrin, *Ostn*) is decreased by FOXO1 \[[3](#feb412898-bib-0003){ref-type="ref"}, [8](#feb412898-bib-0008){ref-type="ref"}\].

Peroxisome proliferator‐activated receptor‐gamma coactivator‐1β (PGC‐1β; *Ppargc1b*) is a transcriptional coactivator of nuclear receptors, which is a homolog of PGC‐1α (*Ppargc1a*) \[[9](#feb412898-bib-0009){ref-type="ref"}, [10](#feb412898-bib-0010){ref-type="ref"}\]. Both PGC‐1β and PGC‐1α are known to increase the mitochondrial content in cells \[[11](#feb412898-bib-0011){ref-type="ref"}, [12](#feb412898-bib-0012){ref-type="ref"}\]. PGC‐1β and PGC‐1α activate nuclear receptors, such as the estrogen‐related receptor \[[10](#feb412898-bib-0010){ref-type="ref"}\], and activate target genes (i.e., medium‐chain acyl CoA dehydrogenase, MCAD, *Acadm*) in skeletal muscles \[[10](#feb412898-bib-0010){ref-type="ref"}, [13](#feb412898-bib-0013){ref-type="ref"}, [14](#feb412898-bib-0014){ref-type="ref"}\]. Indeed, the overexpression of PGC‐1β in skeletal muscles in mice led to increased energy expenditure and an anti‐obesity phenotype \[[10](#feb412898-bib-0010){ref-type="ref"}\]. Regulation of PGC‐1α in skeletal muscles has been well studied. PGC‐1α expression is markedly upregulated during exercise \[[15](#feb412898-bib-0015){ref-type="ref"}, [16](#feb412898-bib-0016){ref-type="ref"}\] and is considered to contribute to the expression of exercise‐related genes, such as those involved in branched‐chain amino acid metabolism \[[17](#feb412898-bib-0017){ref-type="ref"}\]. In contrast, little is known about the regulation of the PGC‐1β gene in skeletal muscles.

In this study, we attempted to analyze the possible FOXO1‐mediated PGC‐1β gene expression, as the level of PGC‐1β mRNA was decreased in the skeletal muscles of FOXO1‐overexpressing Tg mice. Thus, we examined the level of PGC‐1β gene expression in various conditions with altered FOXO1 levels in skeletal muscles and cells.

Materials and methods {#feb412898-sec-0002}
=====================

Animals {#feb412898-sec-0003}
-------

Tg mice overexpressing FOXO1 in skeletal muscles (FOXO1‐Tg) have been previously described \[[3](#feb412898-bib-0003){ref-type="ref"}\]. Skeletal muscle‐specific FOXO1‐KO mice were described previously \[[5](#feb412898-bib-0005){ref-type="ref"}\]. C57BL/6J mice were purchased from Shimizu Laboratory Supplies Co., Ltd. (Kyoto, Japan) and maintained at a constant temperature (24 °C) with fixed artificial light (12‐h light/12‐h dark cycle). All animal experiments were performed in accordance with the guidelines of the Kyoto Prefectural University Committee on Animal Research. The protocol was approved by this committee (no. KPU260407, review board: Y. Tsukamoto).

cDNA microarray analysis {#feb412898-sec-0004}
------------------------

RNA was isolated from skeletal muscle (gastrocnemius) of FOXO1‐Tg mice (age, 25 weeks) and age‐matched wild‐type control mice. Samples from wild‐type (*N* = 6) and FOXO1‐Tg mice (*N* = 5) were pooled and used. RNA was isolated using TRIzol reagent (Thermo Fisher Scientific Inc., Tokyo, Japan) and purified using an RNeasy Mini kit (Qiagen, Hilden, Germany). Each sample was labeled with cyanine 3‐CTP using a Low Input Quick Amp Labeling Kit (Agilent Technologies, Santa Clara, CA, USA). Cyanine 3‐CTP‐labeled cRNA (1.65 μg) was fragmented and hybridized to the Agilent whole mouse genome (8 × 60 K) microarray. Signal detection and data analysis were performed as described previously \[[17](#feb412898-bib-0017){ref-type="ref"}\]. The microarray data were submitted to the Gene Expression Omnibus (GEO) database (<https://www.ncbi.nlm.nih.gov/geo/>). The records have been assigned GEO accession numbers as [GSE146919](http://GSE146919).

Quantitative real‐time RT‐PCR analysis {#feb412898-sec-0005}
--------------------------------------

Total RNA was isolated from skeletal muscles or cells using TRIzol reagent (Thermo Fisher Scientific Inc.). cDNA was synthesized using 500 ng of each RNA sample with ReverTraAce (Toyobo, Tokyo, Japan). Gene expression was measured as described previously \[[18](#feb412898-bib-0018){ref-type="ref"}\]. Fold change for each target gene was calculated as follows: ΔC*~t~* = C*~t~* (target gene) -- C*~t~* (reference gene), ΔΔC*~t~* = ΔC*~t~* (target gene) -- ΔC*~t~* (reference gene). Due to the exponential nature of PCR, 'fold change' was calculated as $2^{- \Delta\Delta C_{t}}$ \[[19](#feb412898-bib-0019){ref-type="ref"}\]. The primer sequences used were as follows: FOXO1, forward 5′‐GCGGGCTGGAAGAATTCAAT‐3′ and reverse 5′‐TCCAGTTCCTTCATTCTGCA‐3′; cathepsin L, forward 5′‐TCTCACGCTCAAGGCAATCA‐3′ and reverse 5′‐AAGCAAAATCCATCAGGCCTC‐3′; PGC‐1β, forward 5′‐AGAGGCACCCAGAGCGAAG‐3′ and reverse 5′‐TTGTGGCATGCTGCAAATG‐3′; MCAD, forward 5′‐GATCGCAATGGGTGCTTTTGATAGAA‐3′ and reverse 5′‐AGCTGATTGGCAATGTCTCCAGCAAA‐3′; PGC‐1α, forward 5′‐CGGAAATCATATCCAACCAG‐3′ and reverse 5′‐TGAGGACCGCTAGCAAGTTTG‐3′; MyoD, forward 5′‐ CGGGACATAGACTTGACAGGC‐3′ and reverse 5′‐ TCGAAACACGGGTCATCATAGA‐3′; myogenin, forward 5′‐ CATGGTGCCCAGTGAATGCAACTC‐3′ and reverse 5′‐ TATCCTCCACCGTGATGCTGTCCA‐3′; 36B4, forward 5′‐GGCCCTGCACTCTCGCTTTC‐3′ and reverse 5′‐TGCCAGGACGCGCTTGT‐3′, and 18S, forward 5′‐GGGAGCCTGAGAAACGGC‐3′ and reverse 5′‐ GGGTCGGGAGTGGGTAATTTT‐3.

Western blotting analysis {#feb412898-sec-0006}
-------------------------

Western blotting analysis was performed as described previously \[[5](#feb412898-bib-0005){ref-type="ref"}\]. The primary antibody used was anti‐FOXO1 \[FoxO1 (C29H4) Rabbit mAb \#2880; Cell Signaling Technology, Danvers, MA, USA\].

Measurement of mitochondrial DNA content {#feb412898-sec-0007}
----------------------------------------

Mitochondrial DNA (mtDNA) content was measured as mtDNA copy number normalized to the copy number of a gene contained in the nuclear genome. The mitochondrial gene used for mtDNA copy estimation was cytochrome c oxidase subunit 2 (COX2), and the copy number of COX2 was normalized to the copy number of the 36B4 gene, contained in the nuclear genome, as described previously \[[20](#feb412898-bib-0020){ref-type="ref"}\].

Measurement of citrate synthase activity {#feb412898-sec-0008}
----------------------------------------

Citrate synthase (CS) activity was measured as described previously \[[21](#feb412898-bib-0021){ref-type="ref"}\].

Denervation, plaster cast, and fasting {#feb412898-sec-0009}
--------------------------------------

For the denervation model, a 4‐ to 5‐mm section of the sciatic nerve in the hindlimb of the mice was removed \[[18](#feb412898-bib-0018){ref-type="ref"}\]. After 12 days, skeletal muscles were collected.

A plaster cast for the mice was created as described previously \[[18](#feb412898-bib-0018){ref-type="ref"}\]. The hindlimb skeletal muscles of the mice were immobilized (unloaded) by the plaster cast. After 11 days, skeletal muscles were collected.

For the fasting experiment, C57BL/6J mice (9 weeks old, male) were fasted for 8 or 24 h. For refeeding, the mice were fasted for 24 h and refed for 4 h. Then, skeletal muscles were collected \[[22](#feb412898-bib-0022){ref-type="ref"}\].

Cells {#feb412898-sec-0010}
-----

C2C12 mouse myoblasts (Riken Cell Bank, Tsukuba, Japan) stably expressing the FOXO1‐estrogen receptor (ER) fusion protein were prepared as previously described \[[4](#feb412898-bib-0004){ref-type="ref"}, [23](#feb412898-bib-0023){ref-type="ref"}, [24](#feb412898-bib-0024){ref-type="ref"}\]. In brief, C2C12 cells were stably transfected with the pBABE retroviral vector expressing fusion proteins containing a constitutively active form of human FOXO1, in which the AKT phosphorylation sites Thr‐24, Ser‐256, and Ser‐319 are replaced with alanine \[FOXO1(3A)\] in‐frame with a modified tamoxifen‐specific version of the ligand‐binding domain murine ER \[[4](#feb412898-bib-0004){ref-type="ref"}, [23](#feb412898-bib-0023){ref-type="ref"}\]. Fusion proteins were restricted to the cytoplasmic compartment until activation with tamoxifen, which caused FOXO1‐ER to relocate to the nucleus, where the FOXO1 moiety then functioned as a transcription factor \[[4](#feb412898-bib-0004){ref-type="ref"}, [23](#feb412898-bib-0023){ref-type="ref"}\]. The cells were then cultured in Dulbecco's modified Eagle's medium supplemented with 10% FBS. The medium was replaced every 2 days until the cells reached confluence. Two days after confluence, the cells (undifferentiated myoblasts) were treated with tamoxifen for 24 h and used for the RNA analysis.

Statistical analyses {#feb412898-sec-0011}
--------------------

Statistical analyses were performed using Student's two‐tailed unpaired *t*‐test for comparisons between two groups, and one‐way analysis of variance followed by Tukey's *post hoc* test for comparisons between three or more groups. Two‐way analysis of variance followed by Tukey's *post hoc* test for FOXO1‐KO mice analysis. *P* \< 0.05 was considered significant.

Results and Discussion {#feb412898-sec-0012}
======================

Decreased PGC‐1β expression in the skeletal muscles of FOXO1‐Tg mice {#feb412898-sec-0013}
--------------------------------------------------------------------

First, we used a skeletal muscle sample of FOXO1‐overexpressing Tg (FOXO1‐Tg) mice \[[3](#feb412898-bib-0003){ref-type="ref"}\]. The skeletal muscle weight of the wild‐type control was 190 ± 9 mg (*N* = 5) and that of the FOXO1‐Tg mice was 117 ± 7 mg (*N* = 5; *P* \< 0.001), reflecting muscle atrophy in the latter group. We performed microarray analysis to understand the gene expression changes caused by FOXO1 overexpression. One‐hundred‐and‐fifty‐three genes were upregulated more than twofold, and 145 genes were downregulated more than 0.5‐fold (Tables [1](#feb412898-tbl-0001){ref-type="table"} and [2](#feb412898-tbl-0002){ref-type="table"}). Microarray data showed decreased PGC‐1β expression in the skeletal muscles of FOXO1‐Tg mice, compared with that in wild‐type control mice (0.44‐fold; Table [2](#feb412898-tbl-0002){ref-type="table"}). In order to confirm the microarray data, we examined the gene expression using real‐time qPCR. As expected, FOXO1 transgene overexpression was observed in the skeletal muscles of the FOXO1‐Tg mice (Fig. [1A](#feb412898-fig-0001){ref-type="fig"}). We observed increased FOXO1 protein levels in the skeletal muscle of FOXO1‐Tg mice (Fig. [1B](#feb412898-fig-0001){ref-type="fig"}). Authentic FOXO1 target gene cathepsin L expression was markedly increased in the FOXO1‐Tg mice (Fig. [1A](#feb412898-fig-0001){ref-type="fig"}), indicating the functional expression of the FOXO1 transgene. At the same time, PGC‐1β gene expression was significantly decreased in the FOXO1‐Tg mice (Fig. [1A](#feb412898-fig-0001){ref-type="fig"}), confirming the microarray data. In addition, the expression of the known PGC‐1β target MCAD was significantly decreased. Thus, FOXO1 overexpression appears to decrease PGC‐1β expression in skeletal muscles.

###### 

List of genes in skeletal muscle with increased expression levels in FOXO1‐Tg mice compared with wild‐type control mice. Top 100 genes are shown.

        SystematicName       GeneName   Description                                                                           Fold (FOXO1‐Tg/ Wild‐type)
  ----- -------------------- ---------- ------------------------------------------------------------------------------------- ----------------------------
  1     NM_025540            Sln        Sarcolipin                                                                            154.62
  2     NM_001081187         Htra4      HtrA serine peptidase 4                                                               66.04
  3     NM_019739            Foxo1      Forkhead box O1                                                                       56.54
  4     NM_010858            Myl4       Myosin, light polypeptide 4                                                           14.98
  5     NM_001134697         Ctxn3      Cortexin 3                                                                            11.60
  6     NM_013803            Casr       Calcium‐sensing receptor                                                              9.63
  7     NM_007836            Gadd45a    Growth arrest and DNA‐damage‐inducible 45 alpha                                       7.61
  8     NM_013492            Clu        Clusterin                                                                             7.22
  9     NM_025359            Tspan13    Tetraspanin 13                                                                        7.18
  10    NM_030695            Lrba       LPS‐responsive beige‐like anchor                                                      6.99
  11    NM_010597            Kcnab1     Potassium voltage‐gated channel, shaker‐related subfamily, beta member 1              5.78
  12    NM_146085            Apbb3      Amyloid beta (A4) precursor protein‐binding, family B, member 3                       5.16
  13    NM_008362            Il1r1      Interleukin 1 receptor, type I                                                        5.07
  14    NM_007913            Egr1       Early growth response 1                                                               4.71
  15    NM_153578            Nipa1      Nonimprinted in Prader‐Willi/Angelman syndrome 1 homolog (human)                      4.62
  16    NM_011044            Pck1       Phosphoenolpyruvate carboxykinase 1, cytosolic                                        4.46
  17    NM_008258            Hn1        Hematological and neurological expressed sequence 1                                   4.36
  18    NM_201256            Eif4ebp3   Eukaryotic translation initiation factor 4E binding protein 3                         4.28
  19    NM_001102405         Acp5       Acid phosphatase 5, tartrate resistant                                                4.15
  20    NM_021282            Cyp2e1     Cytochrome P450, family 2, subfamily e, polypeptide 1                                 4.15
  21    NM_009876            Cdkn1c     Cyclin‐dependent kinase inhibitor 1C (P57)                                            4.15
  22    NM_021282            Cyp2e1     Cytochrome P450, family 2, subfamily e, polypeptide 1                                 4.14
  23    NM_025439            Tmem9      Transmembrane protein 9                                                               4.12
  24    NM_144936            Tmem45b    Transmembrane protein 45b                                                             4.01
  25    NM_008086            Gas1       Growth arrest‐specific 1                                                              4.00
  26    NM_013614            Odc1       Ornithine decarboxylase, structural 1                                                 3.90
  27    NM_011858            Tenm4      Teneurin transmembrane protein 4                                                      3.87
  28    NM_001204959         Retn       Resistin                                                                              3.84
  29    NM_178373            Cidec      Cell death‐inducing DFFA‐like effector c                                              3.76
  30    NM_009605            Adipoq     Adiponectin, C1Q, and collagen domain containing                                      3.69
  31    NM_008161            Gpx3       Glutathione peroxidase 3                                                              3.66
  32    NM_007389            Chrna1     Cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle)                         3.55
  33    NM_025869            Dusp26     Dual specificity phosphatase 26 (putative)                                            3.50
  34    NM_011158            Prkar2b    Protein kinase, cAMP‐dependent regulatory, type II beta                               3.44
  35    NM_175640            Plin1      Perilipin 1                                                                           3.42
  36    NM_001159487         Rbp4       Retinol binding protein 4, plasma                                                     3.37
  37    NM_033037            Cdo1       Cysteine dioxygenase 1, cytosolic                                                     3.37
  38    NM_026929            Chac1      ChaC, cation transport regulator 1                                                    3.37
  39    NM_181072            Myo1e      Myosin IE                                                                             3.35
  40    NM_013459            Cfd        Complement factor D (adipsin)                                                         3.34
  41    NM_029385            Nudt16     Nudix (nucleoside diphosphate linked moiety X)‐type motif 16                          3.34
  42    NM_009675            Aoc3       Amine oxidase, copper containing 3                                                    3.32
  43    NM_009127            Scd1       Stearoyl‐Coenzyme A desaturase 1                                                      3.30
  44    NM_007469            Apoc1      Apolipoprotein C‐I                                                                    3.27
  45    NM_177733            E2f2       E2F transcription factor 2                                                            3.25
  46    NM_013869            Tnfrsf19   Tumor necrosis factor receptor superfamily, member 19                                 3.23
  47    NM_010864            Myo5a      Myosin VA                                                                             3.21
  48    NM_029803            Ifi27l2a   Interferon, alpha‐inducible protein 27 like 2A                                        3.19
  49    NM_010828            Cited2     Cbp/p300‐interacting transactivator, with Glu/Asp‐rich carboxy‐terminal domain, 2     3.14
  50    NM_017370            Hp         Haptoglobin                                                                           3.13
  51    NM_145400            Ube4a      Ubiquitination factor E4A, UFD2 homolog (*S. cerevisiae*)                             3.06
  52    NM_133838            Ehd4       EH‐domain containing 4                                                                3.05
  53    NM_007639            Cd1d1      CD1d1 antigen                                                                         3.05
  54    NM_001013826         Dupd1      Dual specificity phosphatase and pro isomerase domain containing 1                    2.95
  55    NM_023625            Plbd2      Phospholipase B domain containing 2                                                   2.95
  56    NM_013822            Jag1       Jagged 1                                                                              2.93
  57    NM_177409            Tram2      Translocating chain‐associating membrane protein 2                                    2.90
  58    NM_020581            Angptl4    Angiopoietin‐like 4                                                                   2.89
  59    NM_009822            Runx1t1    Runt‐related transcription factor 1; translocated to, 1 (cyclin D‐related)            2.89
  60    NM_146001            Hip1       Huntingtin‐interacting protein 1                                                      2.89
  61    NM_011430            Sncg       Synuclein, gamma                                                                      2.89
  62    NM_007679            Cebpd      CCAAT/enhancer binding protein (C/EBP), delta                                         2.88
  63    NM_011580            Thbs1      Thrombospondin 1                                                                      2.85
  64    NM_008630            Mt2        Metallothionein 2                                                                     2.84
  65    NM_133955            Rhou       Ras homolog gene family, member U                                                     2.83
  66    NM_025888            Kctd20     Potassium channel tetramerization domain containing 20                                2.82
  67    NM_008198            Cfb        Complement factor B                                                                   2.81
  68    NM_019432            Tmem37     Transmembrane protein 37                                                              2.71
  69    NM_013468            Ankrd1     Ankyrin repeat domain 1 (cardiac muscle)                                              2.71
  70    NM_025593            Polr2l     Polymerase (RNA) II (DNA directed) polypeptide L                                      2.70
  71    NM_001198823         App        Amyloid beta (A4) precursor protein (App)                                             2.69
  72    NM_178087            Pml        Promyelocytic leukemia                                                                2.68
  73    NM_138673            Stab2      Stabilin 2                                                                            2.66
  74    NM_007569            Btg1       B‐cell translocation gene 1, antiproliferative                                        2.66
  75    NM_009984            Ctsl       Cathepsin L                                                                           2.63
  76    NM_009801            Car2       Carbonic anhydrase 2                                                                  2.63
  77    NM_008055            Fzd4       Frizzled homolog 4 (Drosophila)                                                       2.60
  78    ENSMUST00000030257   Cachd1     Cache domain containing 1                                                             2.58
  79    NM_146251            Pnpla7     Patatin‐like phospholipase domain containing 7                                        2.58
  80    NM_197986            Tmem140    Transmembrane protein 140                                                             2.58
  81    NM_001198984         Tcof1      Treacher Collins Franceschetti syndrome 1, homolog                                    2.58
  82    NM_009201            Slc1a5     Solute carrier family 1 (neutral amino acid transporter), member 5                    2.54
  83    NM_001145953         Lgals3     Lectin, galactose binding, soluble 3                                                  2.52
  84    NM_133977            Trf        Transferrin                                                                           2.50
  85    NM_001081349         Slc43a1    Solute carrier family 43, member 1                                                    2.50
  86    NM_029083            Ddit4      DNA damage‐inducible transcript 4                                                     2.50
  87    NM_009780            C4b        Complement component 4B                                                               2.50
  88    NM_010097            Sparcl1    SPARC‐like 1                                                                          2.49
  89    NM_001101433         Zcchc24    Zinc finger, CCHC domain containing 24                                                2.48
  90    NM_133198            Pygl       Liver glycogen phosphorylase                                                          2.44
  91    NM_026439            Ccdc80     Coiled‐coil domain containing 80                                                      2.44
  92    NM_019412            Prx        Periaxin                                                                              2.41
  93    NM_148927            Plekha4    Pleckstrin homology domain containing, family A                                       2.41
  94    NM_181390            Mustn1     Musculoskeletal, embryonic nuclear protein 1                                          2.40
  95    NM_001097644         Ccnyl1     Cyclin Y‐like 1                                                                       2.39
  96    NM_026330            Nsmce1     Non‐SMC element 1 homolog (S. cerevisiae)                                             2.38
  97    NM_008037            Fosl2      Fos‐like antigen 2                                                                    2.36
  98    NM_001039386         Nsmf       NMDA receptor synaptonuclear signaling and neuronal migration factor                  2.35
  99    NM_023587            Ptplb      Protein tyrosine phosphatase‐like (proline instead of catalytic arginine), member b   2.32
  100   NM_011785            Akt3       Thymoma viral proto‐oncogene 3                                                        2.32
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###### 

List of genes in skeletal muscle with decreased expression levels in FOXO1‐Tg mice compared with wild‐type control mice. Top 100 genes are shown. PGC‐1β is highlighted.

        SystematicName       GeneName    Description                                                                                        Fold (FOXO1‐Tg/ Wild‐type)
  ----- -------------------- ----------- -------------------------------------------------------------------------------------------------- ----------------------------
  1     NM_010292            Gck         Glucokinase                                                                                        0.06
  2     NM_001081324         Neto2       Neuropilin (NRP) and tolloid (TLL)‐like 2                                                          0.06
  3     NM_001033473         Odf3l2      Outer dense fiber of sperm tails 3‐like 2                                                          0.06
  4     NM_198112            Ostn        Osteocrin                                                                                          0.06
  5     NM_011825            Grem2       Gremlin 2 homolog, cysteine knot superfamily (*Xenopus laevis*)                                    0.06
  6     NM_009867            Cdh4        Cadherin 4                                                                                         0.08
  7     NM_053250            Crip3       Cysteine‐rich protein 3 (Crip3), transcript variant TLP‐B                                          0.09
  8     NM_009700            Aqp4        Aquaporin 4                                                                                        0.10
  9     NM_177787            Slc15a5     Solute carrier family 15, member 5                                                                 0.12
  10    NM_144547            Amhr2       Anti‐Mullerian hormone type 2 receptor                                                             0.13
  11    NM_013467            Aldh1a1     Aldehyde dehydrogenase family 1, subfamily A1                                                      0.14
  12    NM_030017            Rdh12       Retinol dehydrogenase 12                                                                           0.15
  13    NM_011497            Aurka       Aurora kinase A                                                                                    0.16
  14    NM_001081160         Mdga1       MAM domain containing glycosylphosphatidylinositol anchor 1                                        0.16
  15    NM_001013799         Mettl21c    Methyltransferase like 21C                                                                         0.16
  16    NM_001024539         Shc2        SHC (Src homology 2 domain containing) transforming protein 2                                      0.17
  17    NM_144860            Mib1        Mindbomb homolog 1 (Drosophila)                                                                    0.18
  18    NM_176920            Lrtm1       Leucine‐rich repeats and transmembrane domains 1                                                   0.18
  19    NM_016749            Mybph       Myosin binding protein H                                                                           0.18
  20    NM_010061            Dnase1      Deoxyribonuclease I                                                                                0.19
  21    NM_029104            Mss51       MSS51 mitochondrial translational activator (Mss51), nuclear gene encoding mitochondrial protein   0.20
  22    NM_001177841         Otub2       OTU domain, ubiquitin aldehyde binding 2                                                           0.20
  23    NM_010019            Dapk2       Death‐associated protein kinase 2                                                                  0.20
  24    NM_025998            Nkain1      Na+/K+transporting ATPase interacting 1                                                            0.20
  25    NM_011943            Map2k6      Mitogen‐activated protein kinase kinase 6                                                          0.22
  26    NM_194060            Foxo6       Forkhead box O6                                                                                    0.22
  27    NM_028638            Gadl1       Glutamate decarboxylase‐like 1                                                                     0.22
  28    NM_009393            Tnnc1       Troponin C, cardiac/slow skeletal                                                                  0.23
  29    NM_145562            Parm1       Prostate androgen‐regulated mucin‐like protein 1                                                   0.23
  30    NM_010585            Itpr1       Inositol 1,4,5‐trisphosphate receptor 1                                                            0.25
  31    NM_001253822         Irx3        Iroquois‐related homeobox 3 (Drosophila)                                                           0.26
  32    NM_013737            Pla2g7      Phospholipase A2, group VII (platelet‐activating factor acetylhydrolase, plasma)                   0.26
  33    NM_019636            Tbc1d1      TBC1 domain family, member 1                                                                       0.26
  34    NM_016719            Grb14       Growth factor receptor bound protein 14                                                            0.27
  36    NM_015814            Dkk3        dickkopf homolog 3 (*Xenopus laevis*)                                                              0.28
  37    NM_010267            Gdap1       Ganglioside‐induced differentiation‐associated‐protein 1                                           0.29
  38    NM_022314            Tpm3        Tropomyosin 3, gamma                                                                               0.29
  39    NM_007642            Cd28        CD28 antigen                                                                                       0.29
  40    NM_010246            Fzd9        frizzled homolog 9 (Drosophila)                                                                    0.29
  41    NM_026999            Zfp688      Zinc finger protein 688                                                                            0.30
  42    NM_031997            Tmem2       Transmembrane Protein 2                                                                            0.30
  43    NM_016854            Ppp1r3c     Protein phosphatase 1, regulatory (inhibitor) subunit 3C                                           0.30
  44    NM_001159344         Casz1       Castor zinc finger 1                                                                               0.30
  45    NM_027402            Fndc5       Fibronectin type III domain containing 5                                                           0.30
  46    BC019757             Hist1h4i    Histone cluster 1, H4i                                                                             0.30
  47    NM_010859            Myl3        Myosin, light polypeptide 3                                                                        0.30
  48    NM_207161            Dnph1       2\'‐deoxynucleoside 5\'‐phosphate N‐hydrolase 1                                                    0.31
  49    NM_026884            Fam57b      Family with sequence similarity 57, member B                                                       0.32
  50    NM_010861            Myl2        Myosin, light polypeptide 2, regulatory, cardiac, slow                                             0.32
  51    NM_010518            Igfbp5      Insulin‐like growth factor binding protein 5                                                       0.32
  52    NM_027963            Wdr16       WD repeat domain 16                                                                                0.32
  53    NM_001081063         Prss55      Protease, serine, 55                                                                               0.32
  54    NR_037996            Hmga2‐ps1   HIGH‐mobility group AT‐hook 2, pseudogene 1                                                        0.32
  55    NM_027161            Tmem52      Transmembrane protein 52                                                                           0.32
  56    NM_019563            Cited4      Cbp/p300‐interacting transactivator, with Glu/Asp‐rich carboxy‐terminal domain, 4                  0.33
  57    NM_175511            Fam78a      Family with sequence similarity 78, member A                                                       0.33
  58    NM_175276            Fhod3       Formin homology 2 domain containing 3                                                              0.34
  59    NM_018760            Slc4a4      Solute carrier family 4 (anion exchanger), member 4                                                0.34
  60    ENSMUST00000108587   Tnnt1       Troponin T1, skeletal, slow                                                                        0.35
  61    NM_008852            Pitx3       Paired‐like homeodomain transcription factor 3                                                     0.35
  62    NM_080728            Myh7        Myosin, heavy polypeptide 7, cardiac muscle, beta                                                  0.36
  63    NM_018832            Magix       MAGI family member, X‐linked                                                                       0.37
  64    NM_001170488         Tprkb       Tp53rk binding protein                                                                             0.37
  65    NM_030241            Setd8       SET domain containing (lysine methyltransferase) 8                                                 0.37
  66    NM_007431            Alpl        Alkaline phosphatase, liver/bone/kidney                                                            0.37
  67    NM_181577            Ccdc85a     Coiled‐coil domain containing 85A                                                                  0.37
  68    NM_001122683         Bdh1        3‐hydroxybutyrate dehydrogenase, type 1                                                            0.37
  69    NM_011983            Homer2      Homer homolog 2 (Drosophila)                                                                       0.37
  70    NM_011638            Tfrc        Transferrin receptor                                                                               0.37
  71    NM_030179            Clip4       CAP‐GLY domain containing linker protein family, member 4                                          0.37
  72    NM_198190            Ntf5        Neurotrophin 5                                                                                     0.37
  73    NM_010834            Mstn        myostatin                                                                                          0.38
  74    NM_001085378         Myh7b       Myosin, heavy chain 7B, cardiac muscle, beta                                                       0.38
  75    NM_177603            Frat2       Frequently rearranged in advanced T cell lymphomas 2                                               0.38
  76    NM_009519            Wnt11       Wingless‐related MMTV integration site 11                                                          0.39
  77    NM_133363            Myoz3       Myogenin 3                                                                                         0.39
  78    NM_027307            Golm1       Golgi membrane protein 1                                                                           0.39
  79    NM_027678            Zranb3      Zinc finger, RAN‐binding domain containing 3                                                       0.40
  80    NM_001160262         Fam78b      Family with sequence similarity 78, member B                                                       0.40
  81    NM_148958            Osbpl10     Oxysterol binding protein‐like 10                                                                  0.40
  82    EU616813             Mirg        Clone E19 5E_C11 maternally expressed gene 9                                                       0.40
  83    NM_021467            Tnni1       Troponin I, skeletal, slow 1                                                                       0.40
  84    NR_003280            Rs5‐8s1     5.8S ribosomal RNA                                                                                 0.41
  85    NM_080595            Emid1       EMI domain containing 1                                                                            0.41
  86    NM_001109040         Kif21a      Kinesin family member 21A                                                                          0.41
  87    NM_033478            Ly6g6d      Lymphocyte antigen 6 complex, locus G6D                                                            0.41
  88    NM_173745            Dusp18      Dual specificity phosphatase 18                                                                    0.41
  89    NM_018803            Syt10       Synaptotagmin X                                                                                    0.41
  90    NM_001252310         Fam19a5     Family with sequence similarity 19, member A5                                                      0.41
  91    NM_011160            Prkg1       Protein kinase, cGMP‐dependent, type I                                                             0.42
  92    NM_030263            Psd3        Pleckstrin and Sec7 domain containing 3                                                            0.43
  93    NM_010866            Myod1       Myogenic differentiation 1                                                                         0.43
  94    NM_008421            Kcnc1       Potassium voltage‐gated channel, Shaw‐related subfamily, member 1                                  0.43
  96    NM_009107            Rxrg        Retinoid X receptor gamma                                                                          0.44
  97    NM_133249            Ppargc1b    Peroxisome proliferative activated receptor, gamma, coactivator 1 beta                             0.44
  98    NM_008596            Sypl2       Synaptophysin‐like 2                                                                               0.44
  99    NM_001272024         Sema6c      Sema domain, transmembrane domain (TM), and cytoplasmic domain (semaphorin) 6C                     0.44
  100   NM_011103            Prkcd       Protein kinase C, delta                                                                            0.44
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![Gene expression analysis of FOXO1, cathepsin L, PGC‐1β, and MCAD in the skeletal muscles of FOXO1‐overexpressing mice. (A) FOXO1 was remarkably expressed in FOXO1‐Tg mice. Cathepsin L, the target gene of FOXO1, was also increased in FOXO1‐Tg mice. In contrast, the expression of PGC‐1β and MCAD decreased in FOXO1‐Tg mice. Quantitative real‐time RT‐PCR data from wild‐type (WT) control mice were set at 100 arbitrary units. Each value is presented as the mean ± standard error (SE; *N* = 5). Statistical analyses were performed using Student's two‐tailed unpaired *t*‐test. \*\*\**P* \< 0.001, \*\**P* \< 0.01 versus wild‐type. (B) Western blotting analysis of skeletal muscle from FOXO1‐Tg mice.](FEB4-10-1373-g001){#feb412898-fig-0001}

Expression of PGC‐1β gene in skeletal muscles with changed endogenous FOXO1 expression {#feb412898-sec-0014}
--------------------------------------------------------------------------------------

We analyzed the expression of the PGC‐1β gene under other conditions with increased endogenous FOXO1 expression. For one of these conditions, we subjected the skeletal muscles of mice to denervation. After 12 days, we dissected the mice. The skeletal muscle (gastrocnemius) weights were 141 ± 6 mg (control, *N* = 3) and 82 ± 2 mg (denervation, *N* = 4; *P* \< 0.001), showing muscle atrophy associated with the denervation. Increased FOXO1 as well as cathepsin L mRNA expression was also observed in the skeletal muscles with denervation (Fig. [2](#feb412898-fig-0002){ref-type="fig"}). We also observed increased FOXO1 protein levels in skeletal muscles with denervation (data not shown). A marked decrease of PGC‐1β expression, as well as MCAD expression, was observed in the skeletal muscles with denervation (Fig. [2](#feb412898-fig-0002){ref-type="fig"}). Denervation increased 36B4 (reference gene) expression. We used another reference gene (18S), whose expression was not increased by denervation, and observed significant decrease of PGC‐1β expression, as well as MCAD expression (Fig. [2](#feb412898-fig-0002){ref-type="fig"}).

![Gene expression analysis of FOXO1, cathepsin L, PGC‐1β, and MCAD in the skeletal muscles of denervated mice. The expression of FOXO1 increased in mice that had undergone denervation. Cathepsin L was also increased in denervated mice. Denervation significantly reduced the expression of PGC‐1β and MCAD. Quantitative real‐time RT‐PCR data from control samples were set at 100 arbitrary units. Each value is presented as the mean ± SE (control: *N* = 3, denervation: *N* = 4). Statistical analyses were performed using Student's two‐tailed unpaired *t*‐test. \*\*\**P* \< 0.001, \*\**P* \< 0.01, \**P* \< 0.05 versus control.](FEB4-10-1373-g002){#feb412898-fig-0002}

Next, we used skeletal muscles subjected to unloading with a plaster cast. Unloading using a plaster cast for 11 days caused muscle atrophy. The skeletal muscle (gastrocnemius) weight was 150 ± 3 mg for the control group (*N* = 5) and 103 ± 5 mg for the group with a plaster cast (*N* = 4; *P* \< 0.001). The plaster cast increased the mRNA expression of FOXO1 and its target cathepsin L, along with decreased PGC‐1β and MCAD expression (Fig. [3](#feb412898-fig-0003){ref-type="fig"}). Plaster cast also increased 36B4 (reference gene) expression. We used another reference gene (18S), whose expression was not increased by plaster cast, and observed significant decrease in PGC‐1β expression, as well as MCAD expression (Fig. [3](#feb412898-fig-0003){ref-type="fig"}).

![Gene expression analysis of FOXO1, cathepsin L, PGC‐1β, and MCAD in the skeletal muscles of plaster‐casted mice. The expression of FOXO1 and cathepsin L was increased upon unloading using a plaster cast. The expression of PGC‐1β and MCAD was decreased by plaster cast. Quantitative real‐time RT‐PCR data from control samples were set at 100 arbitrary units. Each value is presented as the mean ± SE (control: *N* = 5, casting: *N* = 4). Statistical analyses were performed using Student's two‐tailed unpaired *t*‐test. \*\*\**P* \< 0.001, \*\**P* \< 0.01, \**P* \< 0.05 versus control.](FEB4-10-1373-g003){#feb412898-fig-0003}

We also attempted to apply another condition with changed FOXO1 expression: fasting and refeeding. Fasting for 8 or 24 h increased FOXO1 expression in skeletal muscles. Fasting for 24 h followed by refeeding for 4 h downregulated the FOXO1 mRNA expression. Previously, we confirmed increased endogenous FOXO1 protein levels after 24‐h fasting \[[5](#feb412898-bib-0005){ref-type="ref"}\]. Cathepsin L expression was gradually increased by fasting for 8 and 24 h, but it was not decreased by refeeding for 4 h. Therefore, cathepsin L mRNA may be stable against degradation for this period. PGC‐1β expression was gradually decreased by fasting for 8 and 24 h. Interestingly, refeeding for 4 h after fasting for 24 h recovered the PGC‐1β expression, compared with that upon fasting for 24 h alone (Fig. [4](#feb412898-fig-0004){ref-type="fig"}). MCAD expression was slightly decreased by fasting (8 or 24 h) and not markedly changed by refeeding (Fig. [4](#feb412898-fig-0004){ref-type="fig"}). Taking these findings together, in the skeletal muscles of mice, an inverse correlation was observed between FOXO1 and PGC‐1β (Figs [1](#feb412898-fig-0001){ref-type="fig"}, [2](#feb412898-fig-0002){ref-type="fig"}, [3](#feb412898-fig-0003){ref-type="fig"}, [4](#feb412898-fig-0004){ref-type="fig"}), suggesting that PGC‐1β expression is negatively regulated by FOXO1.

![Gene expression analysis of FOXO1, cathepsin L, PGC‐1β, and MCAD in the skeletal muscles of fasted and refed mice. Fasting for 8 and 24 h increased the expression of FOXO1 and cathepsin L. Subsequent refeeding reduced FOXO1 expression. In contrast, the expression of PGC‐1β was decreased by fasting for 8 and 24 h, and the expression was recovered by refeeding. The MCAD expression was not markedly changed. Quantitative real‐time RT‐PCR data from fed samples were set at 100 arbitrary units. Each value is presented as the mean ± SE (*N* = 6). Statistical analyses were performed using one‐way analysis of variance followed by Tukey's *post hoc* test. \*\*\**P* \< 0.001, \*\**P* \< 0.01, \**P* \< 0.05 versus fed; ^†††^ *P* \< 0.001 versus fast for 8 h; ^§§§^ *P* \< 0.001 versus fast for 24 h.](FEB4-10-1373-g004){#feb412898-fig-0004}

Decreased PGC‐1β expression and decreased markers of mitochondrial density {#feb412898-sec-0015}
--------------------------------------------------------------------------

PGC‐1β is known to increase mitochondrial content \[[12](#feb412898-bib-0012){ref-type="ref"}\]; therefore, we examined mtDNA levels and mitochondrial enzyme CS activity as markers of mitochondrial density. Mitochondrially encoded COX2 (*Cox2*) DNA levels were slightly decreased, and CS activity was also significantly decreased in FOXO1‐Tg mice (Fig. [5A](#feb412898-fig-0005){ref-type="fig"}). In addition, decreased mtDNA levels and decreased CS activity were observed after denervation (Fig. [5B](#feb412898-fig-0005){ref-type="fig"}). Moreover, fasting for 24 h caused decreased mtDNA level and decreased CS activity (Fig. [5C](#feb412898-fig-0005){ref-type="fig"}). Thus, decreased PGC‐1β mRNA levels caused by FOXO1 appeared to lead to decreased functional PGC‐1β protein expression, concomitant with decreased mitochondrial content.

![mtDNA content and CS activity in skeletal muscle. mtDNA content and CS activity in (A). Skeletal muscles of FOXO1‐overexpressing mice. The skeletal muscle weight of the wild‐type control was 127 ± 6 mg (*N* = 5) and that of the FOXO1‐Tg mice was 97 ± 5 mg (*N* = 5; *P* \< 0.01). (B) Skeletal muscles of mice with denervation. The skeletal muscle weights were 138 ± 3 mg (control, *N* = 6) and 90 ± 2 mg (denervation, *N* = 8; *P* \< 0.001). (C) Skeletal muscles of mice with fasting 24 h. The skeletal muscle weights were 138 ± 3 mg (control, *N* = 6) and 119 ± 2 mg (fasting 24 h, *N* = 6; *P* \< 0.001). Each value is presented as the mean ± SE. Statistical analyses were performed using Student's two‐tailed unpaired *t*‐test. \*\*\**P* \< 0.001, \**P* \< 0.05 versus respective control.](FEB4-10-1373-g005){#feb412898-fig-0005}

Attenuation of decreased PGC‐1β expression by fasting in the skeletal muscles of FOXO1‐KO mice {#feb412898-sec-0016}
----------------------------------------------------------------------------------------------

For loss‐of‐function experiments, we used skeletal muscle‐specific FOXO1‐KO mice \[[5](#feb412898-bib-0005){ref-type="ref"}\]. In wild‐type control mice, fasting caused increased FOXO1 mRNA levels concomitant with increased cathepsin L mRNA (Fig. [6](#feb412898-fig-0006){ref-type="fig"}). In FOXO1‐KO mice, FOXO1 mRNA levels were very low in both fed and fasting samples, as expected. In a previous study, we confirmed diminished endogenous FOXO1 protein levels in the skeletal muscle of FOXO1‐KO mice in fed and fasting conditions \[[5](#feb412898-bib-0005){ref-type="ref"}\]. In FOXO1‐KO mice, fasting‐induced cathepsin L mRNA expression was significantly attenuated (Fig. [6](#feb412898-fig-0006){ref-type="fig"}). In wild‐type mice, PGC‐1β mRNA levels were decreased by fasting. On the other hand, the fasting‐induced PGC‐1β mRNA decrease was significantly attenuated in FOXO1‐KO mice. The data indicated that fasting‐caused PGC‐1β mRNA decrease was likely to be mediated by FOXO1.

![Gene expression analysis of the skeletal muscles of FOXO1‐KO mice. Gene expression in skeletal muscle of fed and fasted FOXO1‐KO mice. FOXO1‐KO and wild‐type mice were either allowed *ad libitum* access to food or subjected to a 24‐h fast (wild‐type fed, *n* = 3; wild‐type fasted, *n* = 4; KO fed, *n* = 4; KO fasted, *n* = 4). Expression levels of FOXO1, cathepsin L, PGC‐1β, and MCAD in skeletal muscle are shown. Quantitative real‐time RT‐PCR data from fed wild‐type mice were set at 100 arbitrary units. Each value is presented as the mean ± SE. Statistical analyses were performed using two‐way analysis of variance followed by Tukey's *post hoc* test. \*\*\**P* \< 0.001, \*\**P* \< 0.01. NS, not significant.](FEB4-10-1373-g006){#feb412898-fig-0006}

PGC‐1β gene expression change induced by FOXO1 activation in C2C12 cells {#feb412898-sec-0017}
------------------------------------------------------------------------

In order to understand the causal relationship between FOXO1 expression and PGC‐1β expression, we used a tamoxifen‐inducible FOXO1 activation system in C2C12 myoblast cells. Namely, tamoxifen treatment induces the translocation of FOXO1‐ER fusion protein (FOXO1‐ER) from the cytoplasm to the nucleus and causes FOXO1‐mediated target gene activation \[[4](#feb412898-bib-0004){ref-type="ref"}, [23](#feb412898-bib-0023){ref-type="ref"}\]. In the presence of tamoxifen (for 24 h), FOXO1 mRNA expression remained unchanged (Fig. [7A](#feb412898-fig-0007){ref-type="fig"}), which is consistent with the findings of a previous study \[[4](#feb412898-bib-0004){ref-type="ref"}\]. Cathepsin L expression was increased by tamoxifen treatment, indicating FOXO1 activation. Interestingly, in the presence of tamoxifen (FOXO1 activation), there was a marked decrease of PGC‐1β expression (Fig. [7A](#feb412898-fig-0007){ref-type="fig"}). Thus, PGC‐1β gene expression was negatively regulated by FOXO1 in C2C12 myoblast cells. In this experiment, MCAD expression was slightly increased by tamoxifen treatment.

![Effect of FOXO1 activation on the expression of PGC‐1β in C2C12 cells. (A) Tamoxifen (TAM) was added to FOXO1‐ER cells, and 24 h later, mRNA expression was analyzed. Expression levels of FOXO1, cathepsin L, PGC‐1β, and MCAD are shown. Quantitative real‐time RT‐PCR data from controls were set at 100 arbitrary units. Each value is presented as the mean ± SE (*N* = 6). Statistical analyses were performed using Student's two‐tailed unpaired *t*‐test. \*\*\**P* \< 0.001, \*\**P* \< 0.01 versus control. (B) Time course (3, 6, 8, and 24 h) after tamoxifen treatment; microscopic views were observed, and mRNA expression levels were analyzed. Scale bars, 100 µm. Quantitative real‐time RT‐PCR data from 0 h were set at 100 arbitrary units. Each value is presented as the mean ± SE (*N* = 4). Statistical analyses were performed using Student's two‐tailed unpaired *t*‐test. \*\*\**P* \< 0.001, \*\**P* \< 0.01, \**P* \< 0.05 versus control (vehicle).](FEB4-10-1373-g007){#feb412898-fig-0007}

Forkhead box protein O1 was reported to suppress muscle cell differentiation \[[1](#feb412898-bib-0001){ref-type="ref"}, [25](#feb412898-bib-0025){ref-type="ref"}, [26](#feb412898-bib-0026){ref-type="ref"}\]; therefore, we examined the change in muscle differentiation marker gene expression during this experimental period. We examined the time course of PGC‐1β and differentiation marker gene expression. C2C12 cells expressing FOXO1‐ER were treated with tamoxifen, and at 3, 6, 8, and 24 h after treatment, mRNA expression levels were examined. Three hours after treatment, PGC‐1β and MyoD and myogenin (differentiation marker genes) mRNA levels were decreased (Fig. [7B](#feb412898-fig-0007){ref-type="fig"}). We also observed microscopic views of cells; there were no marked phenotypical changes between the vehicle (control) and tamoxifen treatment groups during this time period (Fig. [7B](#feb412898-fig-0007){ref-type="fig"}). We used cells without differentiation stimuli (not using differentiation medium) in confluent cells. Thus, we consider that the cells did not differentiate in these conditions. Thus, the decreased PGC‐1β mRNA levels were not likely to be caused by decreased differentiation (not a result of the differentiation process), but by direct suppression by FOXO1.

FOXO1 expression and PGC‐1α expression changes {#feb412898-sec-0018}
----------------------------------------------

For comparison, we also examined PGC‐1α (PGC‐1β homologue) expression in the samples used for Figs [1](#feb412898-fig-0001){ref-type="fig"}, [2](#feb412898-fig-0002){ref-type="fig"}, [3](#feb412898-fig-0003){ref-type="fig"}, [4](#feb412898-fig-0004){ref-type="fig"},[6](#feb412898-fig-0006){ref-type="fig"}, and [7](#feb412898-fig-0007){ref-type="fig"} (Fig. [8](#feb412898-fig-0008){ref-type="fig"}). PGC‐1α expression was decreased in FOXO1‐Tg mice and in those subjected to denervation, but not unloading with a plaster cast, while PGC‐1β expression was decreased in these groups. Meanwhile, upon fasting for 8 h, PGC‐1α expression did not change; however, upon fasting for 24 h followed by refeeding, PGC‐1α expression was decreased (Fig. [8](#feb412898-fig-0008){ref-type="fig"}). In FOXO1‐KO mice, fasting (24 h) caused decrease of PGC‐1α expression was attenuated (Fig. [8](#feb412898-fig-0008){ref-type="fig"}). In the case of the tamoxifen‐activated FOXO1‐ER experiment, PGC‐1α expression was not decreased but rather significantly increased (Fig. [8](#feb412898-fig-0008){ref-type="fig"}). Thus, PGC‐1α expression appears not to be simply downregulated by FOXO1 activation. PGC‐1α is also known to increase MCAD expression \[[11](#feb412898-bib-0011){ref-type="ref"}\]. Thus, the increased MCAD level observed in the FOXO1‐ER cells (Fig. [7A](#feb412898-fig-0007){ref-type="fig"}) may be explained by the increased PGC‐1α expression, but other possibilities should also be considered.

![Gene expression of PGC‐1α in skeletal muscles and cells. The expression of PGC‐1α was examined in the samples used in Figs [1](#feb412898-fig-0001){ref-type="fig"}, [2](#feb412898-fig-0002){ref-type="fig"}, [3](#feb412898-fig-0003){ref-type="fig"}, [4](#feb412898-fig-0004){ref-type="fig"},[6](#feb412898-fig-0006){ref-type="fig"}, and [7A](#feb412898-fig-0007){ref-type="fig"}. Each value is presented as the mean ± SE. For FOXO1‐Tg experiment, statistical analyses were performed using Student's two‐tailed unpaired *t*‐test (*N* = 5). \*\**P* \< 0.01 versus wild‐type. For denervation experiment, statistical analyses were performed using Student's two‐tailed unpaired *t*‐test (control: *N* = 3, denervation: *N* = 4). \*\*\**P* \< 0.001 versus control. For casting experiment, statistical analyses were performed using Student's two‐tailed unpaired *t*‐test (control: *N* = 5, casting: *N* = 4). For fasting experiment, statistical analyses were performed using one‐way analysis of variance followed by Tukey's *post hoc* test (*N* = 6). \*\*\**P* \< 0.001 versus fed; ^†††^ *P* \< 0.001 versus fast for 8 h; ^§^ *P* \< 0.05 versus fast for 24 h. For FOXO1‐KO experiment, statistical analyses were performed using two‐way analysis of variance followed by Tukey's *post hoc* test (wild‐type fed, *n* = 3; wild‐type fasted, *n* = 4; KO fed, *n* = 4; KO fasted, *n* = 4). \*\*\**P* \< 0.001, \**P* \< 0.05. For FOXO1‐ER experiment, statistical analyses were performed using Student's two‐tailed unpaired *t*‐test (*N* = 6). \*\*\**P* \< 0.001 versus control.](FEB4-10-1373-g008){#feb412898-fig-0008}

Possible physiological significance and mechanism of FOXO1‐mediated suppressed PGC‐1β expression {#feb412898-sec-0019}
------------------------------------------------------------------------------------------------

In this study, we observed that the activation of FOXO1 suppressed PGC‐1β expression in skeletal muscles and myoblast cells. We obtained a clue regarding the mechanism of PGC‐1β gene regulation, which was previously largely unknown. FOXO1 activation causes skeletal muscle atrophy \[[3](#feb412898-bib-0003){ref-type="ref"}\], and PGC‐1β activation causes increased energy expenditure \[[10](#feb412898-bib-0010){ref-type="ref"}\]. During atrophy with FOXO1 activation, decreased PGC‐1β with decreased energy expenditure appears to be physiologically reasonable, to avoid wasting energy in order to prevent a greater decrease of muscle mass.

Forkhead box protein O1 has been reported to increase the degradation of mitochondria, leading to a decrease in mitochondrial content \[[27](#feb412898-bib-0027){ref-type="ref"}\]. As described in the Introduction, PGC‐1β increases mitochondrial content \[[12](#feb412898-bib-0012){ref-type="ref"}\]. Thus, FOXO1 caused downregulation of PGC‐1β as described in this study, which is consistent with decreased mitochondrial content. Indeed, in FOXO1‐Tg mice, the amount of red muscle fiber, which is rich in mitochondria, is decreased \[[3](#feb412898-bib-0003){ref-type="ref"}\]. Additionally, the skeletal muscle of mice with plaster cast or denervation shows a decreased red muscle fiber level, that is, decreased mitochondria concomitant with increased FOXO1 expression \[[3](#feb412898-bib-0003){ref-type="ref"}, [18](#feb412898-bib-0018){ref-type="ref"}\]. Thus, decreased mitochondrial content with increased FOXO1 expression may be mediated by FOXO1‐induced PGC‐1β suppression.

Meanwhile, how FOXO1 downregulates the PGC‐1β gene is currently unclear. FOXO1 binds to the genomic DNA sequence, with the Daf16 binding element (DBE) (consensus: TT\[G/A\]TTTAC) \[[28](#feb412898-bib-0028){ref-type="ref"}\] or insulin response element (IRE; consensus: TT\[G/A\]TTTTG) \[[29](#feb412898-bib-0029){ref-type="ref"}\]. However, there were no consensus DBE or IRE up to 2 kb upstream from the transcription start site. Meanwhile, FOXO1 has been reported to physically interact with other transcription factors, such as nuclear receptors, and to positively and negatively regulate target gene expression \[[30](#feb412898-bib-0030){ref-type="ref"}, [31](#feb412898-bib-0031){ref-type="ref"}, [32](#feb412898-bib-0032){ref-type="ref"}\]. However, there were no typical nuclear receptor binding sites, such as glucocorticoid (atrophic hormone) receptor response elements (GREs; consensus: AGAACA), up to 2 kb upstream from the transcription site. Meanwhile, Yasui *et al*. \[[8](#feb412898-bib-0008){ref-type="ref"}\] reported Sp1 binding sites are involved in FOXO1‐mediated repression of musclin gene expression. Notably, there are two putative Sp1 binding sites (consensus: GGGGCGGGG) \[[33](#feb412898-bib-0033){ref-type="ref"}\] in the mouse PGC‐1β gene at 0.1 and 1.2 kb upstream from the transcription start site (Fig. [9](#feb412898-fig-0009){ref-type="fig"}). Moreover, Shintaku *et al*. \[[34](#feb412898-bib-0034){ref-type="ref"}\] showed transcription factors MyoD and RelB bind within the first intron of the PGC‐1β gene and activate transcription. FOXO1 may regulate the PGC‐1β gene expression by directly binding to the PGC‐1β promoter, or by interacting with other transcription regulators (such as SP1, MyoD, and RelB) binding to the PGC‐1β promoter. On the other hand, microarray data showed decreased MyoD expression in the skeletal muscles of FOXO1‐Tg mice, compared with that in wild‐type control mice (0.43‐fold; Table [2](#feb412898-tbl-0002){ref-type="table"}). Additionally, we observed decreased MyoD levels in C2C12 cells expressing FOXO1‐ER using tamoxifen treatment (Fig. [7B](#feb412898-fig-0007){ref-type="fig"}). FOXO1 may suppress PGC‐1β gene expression via suppressing MyoD expression. Further work is required to clarify this issue.

![Putative Sp1 binding sites (GGGGCGGGG) in the promoter of the mouse PGC‐1β gene. Upstream of the PGC‐1β gene from +4 to −546 and −1057 to −1306 is shown. The transcription start site is counted as +1. The Sp1 binding sites (GGGGCGGGG) are underlined (−99 to −107 and −1207 to −1215).](FEB4-10-1373-g009){#feb412898-fig-0009}
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